First Patient Treated Worldwide with the new CyberKnife M6 System

Mon Feb 4, 2013 8:30am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

European CyberKnife Center to Offer Patients Advanced Radiosurgery Treatments in
SUNNYVALE, Calif.,  Feb. 4, 2013  /PRNewswire/ -- Accuray Incorporated (Nasdaq:
ARAY), a radiation oncology company, announced today that  the European
CyberKnife Center Munich-Grosshadern  (ECZM) has treated the world's first
patient with the new CyberKnife M6 System. With the installation of the new
system, the  Munich  center, in close cooperation with the University Hospital
of  Munich, is the first to offer cancer patients treatment with the CyberKnife
M6 System, the latest generation of the CyberKnife System. The new System is now
able to provide enhanced quality, a streamlined user interface for treatment
delivery and precision to radiation therapy treatments and continues to provide
clinical capabilities including non-isocentric, non-coplanar robotic beam
delivery and real-time tracking and automatic correction.

"We are pleased to have installed the first CyberKnife M6 System at the European
CyberKnife Center Munich-Grosshadern," said  Joshua H. Levine, president and
chief executive officer of Accuray Incorporated. "The CyberKnife M6 System is
the next generation system and will enable clinicians to provide cancer patients
with truly personalized treatments."

The ECZM is a global pioneer in radiosurgery. Back in 2005, the center was the
first in  Germany  to have installed a CyberKnife System. As of today, the team
of clinicians has treated more than 3,500 patients for intra- and extracranial
tumors using CyberKnife SBRT.  

"It is vital to offer our patients the best possible care. With the CyberKnife
System, we know from experience that extremely accurate outcomes can be
achieved. The new system enables us to treat patients significantly faster. Also
the treatment will be available to a much bigger patient population. With the
CyberKnife Systems we are able to adapt the treatment accurately to the
individual needs of each patient's indication," said Prof. Dr.  Berndt Wowra,
Neurosurgeon and Radiosurgeon.  

Dr.  Alexander Muacevic, Neurosurgeon, Radiosurgeon and president of the
Radiosurgery Society, added: "We will now be able to not only treat small,
well-circumscribed tumors, but also larger and irregularly-shaped target

About the European CyberKnife Center,  Germany
The European CyberKnife Center Munich (ECZM) was the first center to have a
CyberKnife system installed in  Germany. Opened in 2005, it maintains several
close scientific and clinical partnerships among which are the University
Hospital Charite Berlin and the  Stanford University,  California/USA. Moreover,
the ECZM clinically and scientifically cooperates with the University Clinic of 
Munich  (Ludwig-Maximilians-Universitat, LMU), which contributed significantly
to the further development of the technology and the treatment of various
indications with CyberKnife. Until today, the center's team has treated more
than 3,500 patients, most of them (71%) for intracranial lesions or tumors. As
part of the Radiosurgery Society, the team has accompanied and published many
clinical studies (covering topics like e.g. the treatment of spinal tumors,
brain metastases or vestibular schwannoma) for which it is perceived as a
pioneer of radiosurgery in  Germany. For more information please visit  

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.   

Safe Harbor Statement 
Statements made in this press release that are not statements of historical fact
are forward-looking statements and are subject to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release relate, but are not limited, to clinical
applications, clinical results, patient outcomes, and the Company's leadership
position in radiation oncology innovation. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially from expectations, including risks detailed from time to time under
the heading "Risk Factors" in the company's report on Form 10-K filed on 
September 10, 2012, as updated in our Form 10-Q filed on  November 8, 2012  and
as updated periodically by our other filings. Forward-looking statements speak
only as of the date the statements are made and are based on information
available to the Company at the time those statements are made and/or
management's good faith belief as of that time with respect to future events.
The Company assumes no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the extent
required by applicable securities laws.  Accordingly, investors should not place
undue reliance on any forward-looking statements.

SOURCE  Accuray Incorporated

Anja Kleber, Marketing Director, + 33 (0) 1 55 23 20 20,; or
Nadine Gottschling, Edelman Germany, + 49 (0) 69 75 61 99 76,

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.